TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model
Metrics: PDF 2786 views | HTML 3257 views | ?
Hendrik Fritsche1,*, Thorsten Heilmann1,2,*, Robert J. Tower3,*, Charlotte Hauser4, Anja von Au5, Doaa El-Sheikh1, Graeme M. Campbell3, Göhkan Alp1, Denis Schewe6, Sebastian Hübner1, Sanjay Tiwari3, Daniel Kownatzki1, Susann Boretius3, Dieter Adam7, Walter Jonat2, Thomas Becker4, Claus C. Glüer3, Margot Zöller5, Holger Kalthoff1, Christian Schem2,*, Anna Trauzold1,4,*
1Division of Molecular Oncology, Institute for Experimental Cancer Research, CCC-North, University of Kiel, Kiel, Germany
2Department of Gynecology, University Hospital Schleswig-Holstein, Kiel, Germany
3Section Biomedical Imaging, Department of Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Kiel, Germany
4Clinic for General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, Kiel, Germany
5Department of Tumor Cell Biology, University Hospital of Surgery, Heidelberg, Germany
6Department of General Pediatrics, ALL-BFM Study Group, University Hospital Schleswig-Holstein, Kiel, Germany
7Institute of Immunology, University of Kiel, Kiel, Germany
*These authors have contributed equally to this work
Anna Trauzold, e-mail: [email protected]
Keywords: TRAIL-R2, breast cancer, CXCR4, bone metastasis, bone homing
Received: October 02, 2014 Accepted: February 09, 2015 Published: March 25, 2015
Despite improvements in detection, surgical approaches and systemic therapies, breast cancer remains typically incurable once distant metastases occur. High expression of TRAIL-R2 was found to be associated with poor prognostic parameters in breast cancer patients, suggesting an oncogenic function of this receptor. In the present study, we aimed to determine the impact of TRAIL-R2 on breast cancer metastasis. Using an osteotropic variant of MDA-MB-231 breast cancer cells, we examine the effects of TRAIL-R2 knockdown in vitro and in vivo. Strikingly, in addition to the reduced levels of the proliferation-promoting factor HMGA2 and corresponding inhibition of cell proliferation, knockdown of TRAIL-R2 increased the levels of E-Cadherin and decreased migration. In vivo, these cells were strongly impaired in their ability to form bone metastases after intracardiac injection. Evaluating possible underlying mechanisms revealed a strong downregulation of CXCR4, the receptor for the chemokine SDF-1 important for homing of cancers cells to the bone. In accordance, cell migration towards SDF-1 was significantly impaired by TRAIL-R2 knockdown. Conversely, overexpression of TRAIL-R2 upregulated CXCR4 levels and enhanced SDF-1-directed migration. We therefore postulate that inhibition of TRAIL-R2 expression could represent a promising therapeutic strategy leading to an effective impairment of breast cancer cell capability to form skeletal metastases.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.